oa Southern African Journal of Gynaecological Oncology - Sutent significantly improved progression-free survival for patients with advanced pancreatic islet cell tumors : press release
|Article Title||Sutent significantly improved progression-free survival for patients with advanced pancreatic islet cell tumors : press release|
|© Publisher:||Medpharm Publications|
|Journal||Southern African Journal of Gynaecological Oncology|
|Publication Date||Jan 2009|
Pfizer recently announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.1 months in patients treated with Sutent compared to 5.5 months in patients treated with placebo. Researchers today presented these data at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The independent Data Monitoring Committee (DMC) recommended halting the trial earlier this year because Sutent showed significant benefit and the study had met its primary endpoint. Full analysis of the data is ongoing.
Article metrics loading...